Health Economics

Cost Effectiveness

Cost-effectiveness analysis is an increasingly important tool for healthcare decision-making in the context of increasing budgetary constraints, an ever-increasing range of treatment options and the relatively high price of new treatments.1-3

THERAKOS ECP ImmunomodulationTM has been shown to be cost effective in the treatment of both acute and chronic graft-versus-host disease (GvHD).3-5

In addition, studies show that THERAKOS ECP Immunomodulation™ may help avoid the costs associated with immunosuppressing the patient.3,5,6

Cost effectiveness in
acute GvHD

In acute GvHD, THERAKOS ECP ImmunomodulationTM has been proven cost-effective in adults4

Cost effectiveness in
chronic GvHD

In chronic GvHD, THERAKOS ECP ImmunomodulationTM has been proven cost-effective in adults and children3-5,7

References:
1. Hill SR. BMC Med. 2012;10:10; 2. Eichler HG, et al. Value Health. 2004;7(5):518-528; 3. Crespo C, et al. Clin Ther. 2012;34(8):1774-1787; 4. Walczak J, et al. Value Health. 2012;15:A349; 5. de Waure C, et al. Value Health. 2015;18(4):457-466; 6. Knobler R, et al. J Eur Acad Dermatol Venereol. 2014;28 Suppl 1:1-37; 7. THERAKOS™, data on file.